- Home
- NEA vs MRUS Comparison
NEA vs MRUS Comparison
Compare NEA & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEA
- MRUS
- Stock Information
- Founded
- NEA 2002
- MRUS 2003
- Country
- NEA United States
- MRUS Netherlands
- Employees
- NEA N/A
- MRUS N/A
- Industry
- NEA Finance/Investors Services
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- NEA Finance
- MRUS Health Care
- Exchange
- NEA Nasdaq
- MRUS Nasdaq
- Market Cap
- NEA 3.3B
- MRUS 2.8B
- IPO Year
- NEA N/A
- MRUS 2016
- Fundamental
- Price
- NEA $11.53
- MRUS $47.37
- Analyst Decision
- NEA
- MRUS Strong Buy
- Analyst Count
- NEA 0
- MRUS 13
- Target Price
- NEA N/A
- MRUS $85.67
- AVG Volume (30 Days)
- NEA 803.4K
- MRUS 513.2K
- Earning Date
- NEA 01-01-0001
- MRUS 02-26-2025
- Dividend Yield
- NEA 4.23%
- MRUS N/A
- EPS Growth
- NEA N/A
- MRUS N/A
- EPS
- NEA N/A
- MRUS N/A
- Revenue
- NEA N/A
- MRUS $35,932,000.00
- Revenue This Year
- NEA N/A
- MRUS N/A
- Revenue Next Year
- NEA N/A
- MRUS $42.15
- P/E Ratio
- NEA N/A
- MRUS N/A
- Revenue Growth
- NEA N/A
- MRUS N/A
- 52 Week Low
- NEA $9.20
- MRUS $37.77
- 52 Week High
- NEA $11.37
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- NEA 56.22
- MRUS 71.36
- Support Level
- NEA $11.50
- MRUS $39.67
- Resistance Level
- NEA $11.59
- MRUS $41.15
- Average True Range (ATR)
- NEA 0.07
- MRUS 1.71
- MACD
- NEA 0.00
- MRUS 0.86
- Stochastic Oscillator
- NEA 56.25
- MRUS 91.57
About NEA Nuveen AMT-Free Quality Municipal Income Fund of Beneficial Interest Par Value $.01
Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.